Denis Chem Lab Limited has issued the notice for its 45th Annual General Meeting (AGM), scheduled for September 25, 2026. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs (MCA) circulars. The board has recommended a final dividend of ₹2.50 per equity share of face value ₹10 each for the financial year ended March 31, 2026, an increase from ₹1.50 per share in the previous year.

Key Agenda Items

The AGM agenda includes ordinary business items such as the adoption of audited financial statements for FY26 and the re-appointment of Ms. Anar Patel as a director retiring by rotation. Special business items focus on governance and management continuity:

• Re-appointment of Managing Director: Shareholders are asked to pass a special resolution to re-appoint Dr. Himanshu Patel as Managing Director for a period of three years, from August 1, 2026, to July 31, 2029. Dr. Patel, who is currently aged 72, requires shareholder approval under Section 196 of the Companies Act, 2013, as he has attained the age of 70 years.
• Auditor Appointments: The board seeks ratification for the remuneration of M/s. Kiran J. Mehta & Co. as Cost Auditors for FY27 and proposes the appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors for five consecutive financial years from FY27 to FY31.

Financial Context

During FY26, the company reported revenue from operations of ₹18,172.04 lakh (approximately ₹181.72 crore), compared to ₹17,329.97 lakh in FY25. The net profit after tax stood at ₹840.93 lakh, up from ₹807.58 lakh in the prior year. The proposed dividend payout reflects this growth in profitability.

What the Numbers Show

The increase in the final dividend recommendation from ₹1.50 to ₹2.50 per share aligns with the company’s improved bottom line. With net profit rising by approximately 4% YoY while revenue grew by nearly 5%, the higher dividend indicates a willingness to return more capital to shareholders despite modest margin expansion. The total dividend amount is estimated at ₹346.91 lakh.

Voting and Logistics

Remote e-voting will be available from September 22, 2026, to September 24, 2026. The record date for determining dividend eligibility is September 18, 2026. Shareholders holding shares in physical form are urged to update their KYC details with the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, to ensure seamless dividend processing.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE051G01012/10b4cbc6-61f4-481c-ab4a-e8e508bcf904.pdf

Denis Chem Lab reported a net profit of ₹204.52 lakh for the quarter ended June 30, 2026, compared to ₹247.50 lakh in the same period of the previous year. The Ahmedabad-based manufacturer of parenteral products saw its revenue from operations rise 1.7% year-on-year to ₹4,399.67 lakh, up from ₹4,327.59 lakh in Q1FY26.

The company’s Board of Directors approved the unaudited financial results at a meeting held on August 13, 2026. The statutory auditors, Shah & Shah Associates, issued an unmodified opinion on the interim financial information.

Financial Performance

Revenue growth was modest but consistent with the prior year’s trajectory. While cost of materials consumed increased by 5% to ₹2,383.17 lakh from ₹2,270.62 lakh, the company managed to contain other significant expense heads. Employee benefits expense rose 17.2% to ₹419.35 lakh, reflecting ongoing workforce costs, while finance costs declined sharply by 41.8% to ₹10.79 lakh from ₹18.55 lakh.

Earnings per share (EPS) stood at ₹1.47 for the quarter, down from ₹1.78 in Q1FY26. The company recorded no exceptional items or discontinued operations during the period.

What the Numbers Show

A key divergence in the results is the behavior of other income versus operating profitability. Other income surged nearly 50% year-on-year to ₹45.00 lakh from ₹30.02 lakh, contributing significantly to total income. However, this gain was offset by a contraction in net profit, indicating that core operating margins faced pressure despite the rise in non-operating gains. The increase in total expenses (3.8%) outpaced revenue growth (1.7%), suggesting input cost inflation or volume-mix shifts impacted bottom-line efficiency more than top-line expansion.

Regulatory and Operational Notes

The company operates solely in one segment: manufacturing and sales of transfusion solutions in bottles. It has no subsidiaries or associates. The filing notes that figures for the previous quarter ended March 31, 2026, represent balancing figures between audited full-year data and unaudited nine-month figures.

Denis Chem Lab continues to monitor the implementation of the four Labour Codes notified by the Government of India in November 2025. In the previous quarter, the company recorded impacts on gratuity and privilege leave due to changes in wage definitions, as per guidance from the Institute of Chartered Accountants of India. No outstanding defaults on loans or debt securities were reported.